Investor Notes - Phillip Securities (HK) Ltd
Past Investor Notes  
Phillip Home Send to Friends Free Subscription Give Comments 中文版
28 Sep, 2023 (Thursday)

            
AKESO(9926)
Analysis:
Akeso (9926) is a biopharmaceutical company committed to researching, developing, manufacturing and commercialising affordable and high-quality innovative drugs for patients worldwide. Adhering to the clinical value-oriented innovation approach, the Company focuses on oncology, autoimmune and other disease areas with significant global unmet medical need, and continues to develop next-generation innovative new drugs with global first-in-class and best-in-class potential. As of 30 June 2023, the Company has six in-house developed innovative drugs which have received NDA approval or submitted NDA application. For the six months ended 30 June 2023, the Company recorded a profit of approximately RMB2,489.5 million, as compared to a loss of approximately RMB691.9 million for the six months ended June 30, 2022. This is the first time for the Company to achieve halfyear profits, which was mainly attributable to the license income of RMB2,915 million from licensing ivonescimab. In addition, the product sales of cadonilimab and ANNIKO recorded significant increase and contributed to the growth in the Company`s product sales revenue. In the first half of 2023, the Group`s revenue increased by 2,154.4% year-on-year to RMB3,676.9 million. Besides the license income of RMB2,915, the product sales of the Company was RMB794.7 million which grew 167.4% year-on-year. Regarding its product portfolio, as of June 30, 2023, it had over 30 innovative programs covering the areas of oncology, autoimmune and metabolic diseases. 19 of these products are in the clinical trial stage and 6 of which are potential first-in-class or best-in-class bi-specific antibodies. (I do not hold the above stock)
Strategy:
Buy-in Price: $37.00, Target Price: $40.00, Cut Loss Price: $35.50


MICROPORT NEURO(2172)
Analysis:
The Company is a pioneer and the largest domestic company in China's neurointerventional medical device industry, with a comprehensive product portfolio covering three major areas of neurovascular diseases, namely, hemorrhagic stroke, cerebral atherosclerosis stenosis and acute ischemic stroke. The company currently has six approved treatment products and three approved pathway products. In the first half of 2023, the company achieved a revenue of 299 million yuan, a year-on-year increase of+45.2%, and a net profit of 58 million yuan, turning losses into profits year-on-year, with a excellent net profit margin of 19.4%. The Company's current product supply is in short supply, and the capacity utilization rate is approaching saturation. In the future, it will expand production in batches. Centralized procurement is beneficial for domestic pharmaceutical equipment companies with strong competitiveness to expand their market share. As their product market share continues to increase, the company's profit margin will remain high.
Strategy:
Buy-in Price: $10.75, Target Price: $15.10, Cut Loss Price: $8.50



Binhai Investment (2886.HK) - Gas prices expect to fall in 2H, drive financial performance for the year

Binhai Investment Company Limited (Binhai) is principally engaged in the sales of piped natural gas, construction and gas pipeline installation service and gas passing through service. The natural gas business of Binhai Investment and its subsidiaries is distributed in seven provinces and two cities across the country, with a total of 40 gas project companies. At present, the largest shareholder of Binhai Investment is Tianjin TEDA Investment Holding Company, holding 40.00% of Binhai's shares, and the second largest shareholder is Sinopec Great Wall Gas Investment Company, holding 29.99% of Binhai's shares.

Suffer from rising purchase cost of natural gas in 2022, 1H margins under pressure

In FY2022, total revenue of Binhai amounted to HK$6102 million (FY2021: HK$4843 million), representing an increase of 26.0% YoY. Profit attributable to equity owners of the Company was HK$326 million (FY2021: HK$400 million), representing a decrease of 18.5% YoY. Profit attributable to equity owners of the company excluding the net foreign exchange loss recognized (FY2022: net exchange loss of HK$84 million) in profit or loss amounted to HK$410 million, representing an increase of 9% YoY. The number of regular customers from the construction and installation of gas engineering works of the company increased by 106 thousand, down by 35% YoY, and the aggregate number of customers amounted to 2299 thousand. The recorded sales volume of piped natural gas was 2.03 billion cubic metres, up by 3% YoY, among which the sales volume of pipeline gas amounted for 1.44 billion cubic metres, up by 15% YoY, and achieved 0.59 billion cubic metres of natural gas pipeline transmission for the year, down by 17% YoY. Gross profit was HK$727 million (FY2021: HK$855 million) and the gross profit margin was 11.9% (FY2021: 17.7%). The decrease in gross profit margin was mainly due to the increase in purchase cost of natural gas.

In 1HFY2023, total revenue of Binhai amounted to HK$3119 million (1HFY2021: HK$3047 million), representing an increase of 2.4% YoY. As the high price of gas supply last year was extended to the 1Q of 2023, caused the cost increased, and the real estate industry continued to operate at a low level, which affected the performance of the connection business. During the period, the gross profit fell by 11.4% YoY to HK$384 million; the gross profit margin dropped to 12.3% (1HFY2022: 14.2%). The profit attributable to owners of the company was HK$166 million during the period, representing a decrease of 35.5% YoY. Such decrease was mainly because of the decrease of gross profit and the increase of finance costs. Basic EPS were HK$12.31 cents, representing a decrease of HK$6.78 cents for the corresponding period last year.

In terms of operating segments, sales of piped natural gas amounted to HK$2790 million, representing an increase of 5%, accounting for about 89.6% of total revenue, due to the increase in natural gas sales volume and the increase in unit price of sales. During the Period, the sales volume of piped natural gas by domestic and industrial users was approximately 183 million cubic meters and 581 million cubic meters respectively, consumption of piped natural gas amounted to 6,433 x 106 and 20,408 x 106 mega-joules respectively, a slight decrease of 0.8% and an increase of 10.0% YoY. The overall pipeline gas sales volume was 764 million cubic meters, a YoY increase of about 7.2%, and has reached about 50% of the FY2023 target. In terms of gross difference, it has increased by RMB 0.03 YoY in 1HFY2023, and increased by RMB 0.05 MoM, indicating that the recovery of gross difference is optimistic.

Income from construction and gas pipeline installation service (constructs gas pipelines for its clients and connects such pipelines to the company's main gas pipeline networks. The company then charges construction and gas pipeline installation service fees from industrial and commercial customers, property developers and property management companies) amounted to approximately HK$300 million, representing a decrease of 11% YoY, accounting for about 9.6% of total revenue. During the period, the number of new customer contracts increased by exceeded 61,000, and the cumulative number of customers exceeded 2.36 million, representing a 4.5% YoY growth. As at 30 June 2023, the aggregate length of city medium-pressure gas pipeline networks was 3,825 kilometers, representing an increase of 104 kilometers, while the aggregate length of high-pressure and sub-high-pressure gas pipeline networks was 649 kilometers, representing an increase of 1 kilometer from the length of 648 kilometers as at 31 December 2022.

For the gas passing through service, the company transports gases for clients through gas pipeline networks and charges passing through fees. During the Period, the volume of gases transported by the company for its clients amounted to 313 million cubic meters and gas passing through service income amounted to HK$26 million, representing a decrease of 17%, accounting for about 0.8% of total revenue.

Gas prices continue to fall in 2H, drive financial performance for the year

In the first half of 2023, national natural gas consumption reached 194.1 billion cubic meters, representing a year-on-year increase of 5.6%. In its quarterly Natural Gas Market Report, the International Energy Agency indicated that it expects China's natural gas consumption to grow by more than 6% in 2023, providing support to the Asia region's overall natural gas consumption growth of nearly 3%. Last year, the industry was plagued by the problem of low dollar margins and the high price of gas supply was extended to the first quarter of this year. Nevertheless, Binhai managed to stabilize its dollar margins in the first half of the year through by the recovery of domestic consumption and favorable policies for the industry. The average monthly Henry Hub Natural Gas Spot Price in the US fell by 34% in the first half of 2023, while the price of natural gas in Europe fell by more than 60% this year. Looking ahead to the second half of the year, gas prices will continue to fall, and the rebound in gross profit will be supported by the increase in gas sales prices. Coupled with the resilience of the company's business income, the rebound in gross profit is expected to drive the Binhai's financial performance for the year as a whole.

Investment Thesis

Since the beginning of the year, a lot of places in China have been promoting the improvement of the upstream and downstream price linkage mechanism for natural gas. Since June, the local development and reform commissions have successively introduced policies for residents to follow the price. As of August 2023, A total of 11 subsidiaries of the company in Hebei, Shandong and Jiangsu have completed price adjustments, ranging from RMB 0.16 to RMB 0.47, with an increase ranging from 5.7% to 19.2%. It is expected to have a certain boost to further repairing the gross difference in the 2H of 2023. The improvement of the price adjustment mechanism is conducive to the recovery and stability of natural gas price differentials, and it eases the procurement pressure of city fuel enterprises. In addition, Sinopec Natural Gas has also agreed to support the Group in lowering the cost of natural gas procurement through trading and the formation of a profit model for the trading business through its superiority in upstream resources, assist the company to meet the requirements of relevant natural gas storage and peak-shaving policy requirements and the development of gas trading business, and help the company connect upstream resources and downstream markets to open up the industrial chain. In the future, there will still be room for natural gas price rationalization adjustment, and the consumption attributes of natural gas will continue to be strengthened. In terms of business expansion, the company stated that it is accelerating the development of the integrated energy business. In addition to provide comprehensive customized development and utilization solutions for new and clean energy such as photovoltaic and geothermal energy in the TEDA Science and Technology Innovation City. Binhai Investment (Tianjin) and Sinopec New Star (Tianjin) New Energy Company Limited entered into the Cooperation Framework Agreement for Integrated Energy Project to cooperate closely in the fields of energy integrated management, integrated energy development, distributed energy planning, construction, and operation; Meanwhile, the company also entered into a strategic framework agreement with Tianjin Capital Environmental Protection Group on the heating service of the energy supply project in Balitai Town, and jointly promote the comprehensive energy heating method that combines regenerative water source heat pumps and gas boilers. We expect FY2023E-FY2024E EPS to be HK$0.224 and HK$0.290 respectively, with PT of HK$2.20, implies a FY2023E P/E of 9.9x (~5-yrs historical average). Our investment rating is “Buy”.

Risk factors

1) Natural gas procurement costs rise more than expected; 2) Large fluctuations in RMB; 3) Economic recovery momentum slower than expected.

Financial

Click Here for PDF format...




Recommendation on 28-9-2023
RecommendationBuy
Price on Recommendation Date$ 1.500
Suggested purchase priceN/A
Target Price$ 2.200
Writer Info
Eric Li
(Research Analyst)
Tel: (+852 2277 6516)
Email:
erichyli@phillip.com.hk

Local Index
       Index    Change   Change%

World Index
       Index    Change   Change%
  

A-H spread
Stock Code H share
Price
A share
Price
H share
discount


Oversea Research Reports


Investment Service Centre



Enquiry : 2277 6666 OR investornotes@phillip.com.hk
If you cannot read this e-mail in the proper format, please click here to view the web version.

Information contained herein is based on sources that Phillip Securities (Hong Kong) Limited and/or its affiliates ( the “Group”) believe to be accurate. The Group does not bear responsibility for any loss occasioned by reliance placed upon the contents hereof. The Group (or its employees) may have interests in relevant investment products. For details of different products’ risks, please view the Risk Disclosures Statement on http://www.phillip.com.hk.

If you DO NOT wish to receive further marketing emails from us, please click HERE to opt-out.

版權所有, 翻印必究。

Copyright(C) 2023 Phillip Securities (HK) Ltd. All Rights Reserved.